Impact of aetiological treatment on conventional and multiplex serology in chronic chagas disease

PLoS Neglected Tropical Diseases

Volumn 5, Issue 9, 2011, Pages

  Viotti, Rodolfo ^a   Vigliano, Carlos ^a   Álvarez, María Gabriela ^a   Lococo, Bruno ^a   Petti, Marcos ^a   Bertocchi, Graciela ^a   Armenti, Alejandro ^a   de Rissio, Ana María ^b   Cooley, Gretchen ^c   Tarleton, Rick ^c   Laucella, Susana ^b  

^a Hospital Eva Peron   (Argentina)

^b Instituto Nacional de Diagnostico e Investigacion de la Enfermedad de Chagas Dr Mario Fatala Chaben   (Argentina)

^c UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZNIDAZOLE; ANTIPROTOZOAL AGENT; NITROIMIDAZOLE DERIVATIVE; PROTOZOON ANTIBODY;

ADULT; AGE DISTRIBUTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARGENTINA; ARTICLE; CHAGAS DISEASE; CHRONIC DISEASE; CONTROLLED STUDY; ECG ABNORMALITY; ENDEMIC DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; PARASITE LOAD; SEROCONVERSION; SEROLOGY; TRYPANOSOMA CRUZI; BLOOD; DRUG MONITORING; FOLLOW UP; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; PARASITOLOGY;

ADULT; ANTIBODIES, PROTOZOAN; ANTIPROTOZOAL AGENTS; ARGENTINA; CHAGAS DISEASE; CHRONIC DISEASE; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NITROIMIDAZOLES; TRYPANOSOMA CRUZI;

EID: 80053455458     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001314     Document Type: Article

References (41)

1. Moncayo A, Silveira AC, (2009) Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Mem Inst Oswaldo Cruz 104: 17-30.
2. Gascón J, Albajar P, Cañas E, Flores M, Gómez i Prat J, et al. (2007) Diagnóstico, manejo y tratamiento de la cardiopatía chagásica crónica en áreas donde la infección por Trypanosoma cruzi no es endémica. Rev Esp Cardiol 60: 285-93.
3. Schmunis GA, (2007) Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem Inst Oswaldo Cruz 102: 75-85.
4. World Health Organization (1991) Control of Chagas disease. Report of aWHO Expert Committee. World Health Organ Tech Rep Ser 811: 1-95.
5. Viotti R, Vigliano C, Armenti H, Segura E, (1994) Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J 127: 151-62.
6. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, et al. (2006) Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment. Ann Intern Med 144: 724-34.
7. Fabbro D, Streiger M, Arias E, Bizal ML, Del Barco M, et al. (2007) Tripanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Rev Soc Bras Med Trop 40: 1-10.
8. Lauria-Pires L, Braga MS, Vexenat AC, Nitz N, Simões-Barbosa A, et al. (2000) Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. Am J Trop Med Hyg 63: 111-8.
9. Cançado JR, (1999) Criteria of Chagas Disease Cure. Mem Inst Oswaldo Cruz 94: 331-335.
10. Gallerano RR, Sosa RR, (2000) Interventional study in the natural evolution of Chagas disease. Evaluation of specific antiparasitic treatment. Retrospective-prospective study of antiparasitic therapy. Rev Fac Cien Med Univ Nac Cordoba 57: 135-62.
11. Laucella SA, Mazliah DP, Bertocchi G, Alvarez MG, Cooley G, et al. (2009) Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. Clin Infect Dis 49: 1675-84.
12. Sánchez Negrette O, Sánchez Valdez FJ, Lacunza CD, García Bustos MF, Mora MC, et al. (2008) Serological evaluation of specific-antibody levels in patients treated for chronic Chagas' disease. Clin Vaccine Inmunol 15: 297-302.
13. Sosa Estani S, Segura E, (1999) Tratamiento de la infección por T cruzi en fase indeterminada. Experiencia y normatización actual en la Argentina. Medicina (Buenos Aires) 59: 166-170.
14. WHO Technical Report Series 905 (2002) Control of Chagas disease, Aetiological treatment. Geneva, Switzerland, 1-109.
15. Bern C, Montgomery SP, Herwaldt BL, Rassi A Jr, Marin-Neto JA, et al. (2007) Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA 298: 2171-81.
16. Kuschnir E, Sgammini H, Castro R, Evequoz C, Ledesma R, et al. (1985) Valoración de la función cardiaca por angiografía radioisotópica, en pacientes con cardiopatía chagásica crónica. Arq Bras Cardiol 45: 249-56.
17. Cooley G, Etheridge RD, Boehlke C, Bundy B, Weatherly DB, et al. (2008) High Throughput Selection of Effective Serodiagnostics for Trypanosoma cruzi infection. PlosNTDS; 2: e316.
18. Sosa-Estani S, Viotti R, Segura E, (2009) Therapy, diagnosis and prognosis of chronic Chagas disease: insight gained in Argentina. Mem Inst Oswaldo Cruz 104: 167-80.
19. Fernandes CD, Tiecher FM, Balbinot MM, Liarte DB, Scholl D, et al. (2009) Efficacy of benznidazole treatment for asymptomatic chagasic patients from state of Rio Grande do Sul evaluated during a three years follow-up. Mem Inst Oswaldo Cruz 104: 27-32.
20. Francolino SS, Antunes AF, Talice R, Rosa R, Selanikio J, et al. (2003) New evidence of spontaneous cure in human Chagas' disease. Rev Soc Bras Med Trop 36: 103-7.
21. Pinto Dias JC, Dias E, Filho OM, Vitelli-Avelar D, Correia D, et al. (2008) Further evidence of spontaneous cure in human Chagas disease. Rev Soc Bras Med Trop 41: 505-506.
22. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, et al. (2005) Clinical predictors of chronic chagasic myocarditis progression. Rev Esp Cardiol 58: 1037-44.
23. Bertocchi G, Álvarez MG, Pérez D, Armenti A, Viotti R, et al. (2008) Evaluación inmunológica del tratamiento con benznidazole en la enfermedad de Chagas crónica. Rev Argent Cardiol 76: 260-265.
24. Murcia L, Carrilero B, Muñoz MJ, Asunción Iborra M, Segovia M, (2010) Usefulness of PCR for monitoring benznidazole response in patients with chronic Chagas' disease: a prospective study in a non-disease-endemic country. J Antimicrob Chemother 65: 1759-64.
25. Siegrist CA, Aspinall R, (2009) B-cell responses to vaccination at the extremes of age. Nat Rev Immunol. 9: 185-94.
26. Amanna IJ, Carlson NE, Slifka MK, (2007) Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 357: 1903-15.
27. Slifka MK, Ahmed R, (1998) Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr Opin Immunol 10: 252-8.
28. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, et al. (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350: 2572-81.
29. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, et al. (2006) Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 6: 741-50.
30. Tarleton R, (2001) Parasite persistence in the aetiology of Chagas disease. Int J Parasitol 31: 550-54.
31. Higuchi ML, Benvenuti LA, Reis MM, Metzger M, (2003) Pathophysiology of the heart in Chagas disease: current status and new developments Cardiovascular Research 60: 96-107.
32. Laucella SA, Postan M, Martin D, Hubby Fralish B, Albareda MC, et al. (2004) Frequency of interferon- gamma-producing T cells specific for Trypanosoma cruzi inversely correlates with disease severity in chronic human Chagas disease. J Infect Dis 189: 909-18.
33. Albareda M C, Laucella SA, Álvarez MG, Armenti AH, Bertocchi G, et al. (2006) Trypanosoma cruzi modulates the profile of memory CD8 T cells in chronic Chagas disease patients. Int. Immunol 18: 465-471.
34. Fortes Araujo F, Silva Gomes J, Costa Rocha MO, Williams-Blangero S, Martins Pinheiro V, el al, (2007) Potential role of CD4+CD25HIGH regulatory T cells in morbidity in Chagas disease. Frontiers in Bioscience 12: 2797-2806.
35. Poncini CV, Giménez G, Pontillo CA, Alba-Soto CD, de Isola ELD, et al. (2010) Central role of extracellular signal-regulated kinase and Toll-like receptor 4 in IL-10 production in regulatory dendritic cells induced by Trypanosoma cruzi. Molecular Immunology 47: 1981-1988.
36. da Matta Guedes PM, Gutierrez FR, Maia FL, Milanezi CM, Silva GK, et al. (2010) IL-17 produced during Trypanosoma cruzi infection plays a central role in regulating parasite-induced myocarditis. PLoS Negl Trop Dis 4 (2): e604.
37. Bustamante JM, Bixby LM, Tarleton RL, (2008) Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease. Nat Med 14: 542-50.
38. Fernández MC, González Cappa SM, Solana ME, (2010) Trypanosoma cruzi: immunological predictors of benznidazole efficacy during experimental infection. Experimental Parasitology 124: 172-80.
39. Viotti R, Vigliano C, (2007) Etiological treatment of chronic Chagas disease: neglected "evidence" by evidence-base medicine. Expert Rev Anti Infect Ther 5: 717-726.
40. Araújo MSS, Martins-Filho OA, Pereira MES, Brener Z, (2000) A combination of benznidazole and ketaconazole enhances efficacy of chemotherapy of experimental Chagas disease. JAC 45: 819-824.
41. Higo H, Miura S, Horio M, Mimori T, Hamano S, et al. (2004) Genotypic variation among lineages of Trypanosoma cruzi and its geographic aspects. Parasitology International 53: 337-344.